Clinical association between pharmacogenomics and adverse drug reactions

Zhi Wei Zhou, Xiao Wu Chen, Kevin B. Sneed, Yin Xue Yang, Xueji Zhang, Zhi Xu He, Kevin Chow, Tianxin Yang, Wei Duan, Shu Feng Zhou

Research output: Contribution to journalReview articlepeer-review

Abstract

Adverse drug reactions (ADRs) are a major public health concern and cause significant patient morbidity and mortality. Pharmacogenomics is the study of how genetic polymorphisms affect an individual's response to pharmacotherapy at the level of a whole genome. This article updates our knowledge on how genetic polymorphisms of important genes alter the risk of ADR occurrence after an extensive literature search. To date, at least 244 pharmacogenes identified have been associated with ADRs of 176 clinically used drugs based on PharmGKB. At least 28 genes associated with the risk of ADRs have been listed by the Food and Drug Administration as pharmacogenomic biomarkers. With the availability of affordable and reliable testing tools, pharmacogenomics looks promising to predict, reduce, and minimize ADRs in selected populations.

Original languageEnglish (US)
Pages (from-to)589-631
Number of pages43
JournalDrugs
Volume75
Issue number6
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Clinical association between pharmacogenomics and adverse drug reactions'. Together they form a unique fingerprint.

Cite this